Shamburg News · 8-K filed Nov 17, 2026, 5:11 PM EST

Gain Therapeutics Reports 12-Month Phase 1b Clinical Data for Rexaceract

GANX · Gain Therapeutics, Inc.

  • Other event
  • Materiality: medium

On November 17, 2026, Gain Therapeutics, Inc. issued a press release presenting clinical data from its Phase 1b study of rexaceract. As of November 1, 2026, all 13 evaluable patients had completed 12 months of daily oral dosing, with MDS-UPDRS scores stable versus baseline and no overall disease progression. Among 11 evaluable Parkinson's patients with CSF samples, glucosylsphingosine levels were reduced or unchanged after 90 days, while one participant later diagnosed with multiple system atrophy showed a change in the opposite direction and no meaningful clinical response; the company reported that rexaceract was generally well tolerated over 12 months.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001104659-26-129142.

Written from the filing by Shamburg Markets. Figures are as reported by the company.